PPI-1019
PPI-1019 had been in phase I/II clinical trials by Praecis Pharmaceuticals (acquired by GlaxoSmithKline in 2007) for the treatment of Alzheimer's disease(AD). However, this study had been discontinued.
General Information
Update Date：2016-04-29
- Drug Name：
- PPI-1019
- Research Code：
- PPI-1019; Apan
- Trade Name：
- MOA：
- Amyloid beta-protein inhibitor
- Indication：
- Alzheimer's disease (AD)
- Status：
- Phase Ⅱ (Discontinued)
- Company：
- GlaxoSmithKline (Originator)
- Sales：
- ATC Code：
Chemical Structure
Update Date：2015-11-18
|
Molecular Weight | 650.85 | ||||||||||||
| Formula | C36H54N6O5 | |||||||||||||
| CAS No. | 290828-45-4 (PPI-1019); | |||||||||||||
| Chemical Name | D-Leucinamide, N-methyl-D-leucyl-D-valyl-D-phenylalanyl-D-phenylalanyl- | |||||||||||||
| PPI-1019 （Free Acid/Base）Parameters： | ||||||||||||||
|
||||||||||||||
| *：Calculated by ACD/Labs software V11.02. | ||||||||||||||